LifeSciences BC > News > Member Announcements

DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates

February 13, 2020
DelMar Pharmaceuticals Inc.

“We are pleased with the pace of progress of both trials, which in some cases have enrolled patients faster than our previous forecasts. We are seeing rapid progress with encouraging survival benefits in both our Phase 2 trials per recent announcements and publications, and look forward to sharing our upcoming update of clinical data at … Continue reading DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates

Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in the Treatment of GI Cancers

February 10, 2020
Bold Therapeutics Inc.

VANCOUVER, British Columbia, Feb. 10, 2020 /PRNewswire/ — Bold Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel anti-cancer therapies, announced that it has received clearance from Health Canada to initiate a Phase 1b trial of its first-in-class anti-resistance therapeutic, BOLD-100, in combination with FOLFOX for the treatment of gastric, pancreatic, colorectal and bile duct cancers. “Based on compelling preclinical efficacy … Continue reading Bold Therapeutics to Initiate Phase 1b Trial of BOLD-100 in the Treatment of GI Cancers

Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer

February 10, 2020
Arbutus Biopharma

Arbutus expects to announce AB-729 Preliminary Phase 1a/1b Data late Q12020 WARMINSTER, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), announced today its decision to discontinue AB-452, its first generation orally available hepatitis B (HBV) specific RNA-destabilizer, and to continue research and development of a next generation oral HBV RNA-destabilizer. In October 2018, Arbutus announced its … Continue reading Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer

Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day

February 6, 2020
Neoleukin Therapeutics, Inc.

SEATTLE, Feb. 06, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum | Oncology Day in New York City on Thursday, February 13, 2020 at 10 a.m. Eastern. A live audio webcast of the … Continue reading Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day

Precision Medicine Being Advanced Through Data Privacy and Security

February 5, 2020
PHEMI Systems

Vancouver, British Columbia, February 4, 2020 – The Vancouver Prostate Centre is launching a collaboration with Roche and PHEMI Systems aimed at finding new insights into precision medicine and oncology treatment with help from the most advanced technology in data privacy and security. Dr. Colin Collins, a professor in the Department of Urological Sciences at the University of British Columbia, a senior research scientist … Continue reading Precision Medicine Being Advanced Through Data Privacy and Security

DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020

February 5, 2020
DelMar Pharmaceuticals Inc.

SAN DIEGO, Feb. 5, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Mr. Saiid Zarrabian, Chief Executive Officer of DelMar will attend the 22nd Annual BIO CEO & Investor Conference being held on February 10 and 11, … Continue reading DelMar Pharmaceuticals to Attend the 22nd Annual BIO CEO & Investor Conference in New York City February 10 and 11, 2020

DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

January 29, 2020
DelMar Pharmaceuticals Inc.

February Issue of “Glioma” Highlights Positive Progression-Free Survival Data SAN DIEGO, Jan. 29, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the publication of previously released interim clinical data in the February 2020 issue of peer-reviewed journal, Glioma.  The … Continue reading DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Dr. Chonnettia Jones joins MSFHR as Vice President, Research

January 28, 2020
Michael Smith Foundation for Health Research

Dr. Chonnettia Jones, a respected scientist with extensive health research funding experience, joins MSFHR as vice president, research effective April 14, 2020. In her role, Chonnettia will lead our funding programs, ensuring support for our province’s talented health researchers in improving the health of British Columbians and their health system.  She will also guide our … Continue reading Dr. Chonnettia Jones joins MSFHR as Vice President, Research

Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares

January 27, 2020
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Jan. 27, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. The gross proceeds to Xenon from the … Continue reading Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares

Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares

January 23, 2020
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. The gross proceeds to Xenon from the offering, … Continue reading Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares